Beyond the pill: contraception and the prevention of hereditary ovarian cancer
Abstract BRCA1 and BRCA2 mutation carriers face an elevated lifetime risk of developing ovarian cancer. Oral contraceptives have been shown to significantly decrease the risk of ovarian cancer by approximately 50% in this high-risk population. Changes in contraceptive formulations and patterns of us...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-06-01
|
| Series: | Hereditary Cancer in Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13053-022-00227-z |
| _version_ | 1811248044031606784 |
|---|---|
| author | Yue Yin Xia Joanne Kotsopoulos |
| author_facet | Yue Yin Xia Joanne Kotsopoulos |
| author_sort | Yue Yin Xia |
| collection | DOAJ |
| description | Abstract BRCA1 and BRCA2 mutation carriers face an elevated lifetime risk of developing ovarian cancer. Oral contraceptives have been shown to significantly decrease the risk of ovarian cancer by approximately 50% in this high-risk population. Changes in contraceptive formulations and patterns of use over time have introduced lower hormonal dosages, different steroid types and non-oral routes of administration. Specifically, there has been a considerable shift in patterns of contraceptive use and the increase in the uptake of non-oral, long-acting, reversible contraception (e.g., intrauterine devices, implants, injections) has corresponded to a decline in oral contraceptive pill use. Whether or not these other methods confer a protective effect against ovarian cancer in the general population is not clear. To our knowledge, there have been no such studies conducted among BRCA mutation carriers. Furthermore, the impact of these changes on the risk of developing ovarian cancer is not known. In this article, we will review the existing epidemiologic evidence regarding the role of contraceptives and the risk of ovarian cancer with a focus on women with a BRCA1 or BRCA2 mutation. We will discuss recent findings and gaps in the knowledge while extrapolating from studies conducted among women from the noncarrier population. |
| first_indexed | 2024-04-12T15:21:09Z |
| format | Article |
| id | doaj.art-e84d20654867439286971a84863deb24 |
| institution | Directory Open Access Journal |
| issn | 1897-4287 |
| language | English |
| last_indexed | 2024-04-12T15:21:09Z |
| publishDate | 2022-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Hereditary Cancer in Clinical Practice |
| spelling | doaj.art-e84d20654867439286971a84863deb242022-12-22T03:27:28ZengBMCHereditary Cancer in Clinical Practice1897-42872022-06-012011910.1186/s13053-022-00227-zBeyond the pill: contraception and the prevention of hereditary ovarian cancerYue Yin Xia0Joanne Kotsopoulos1Women’s College Research Institute, Women’s College HospitalWomen’s College Research Institute, Women’s College HospitalAbstract BRCA1 and BRCA2 mutation carriers face an elevated lifetime risk of developing ovarian cancer. Oral contraceptives have been shown to significantly decrease the risk of ovarian cancer by approximately 50% in this high-risk population. Changes in contraceptive formulations and patterns of use over time have introduced lower hormonal dosages, different steroid types and non-oral routes of administration. Specifically, there has been a considerable shift in patterns of contraceptive use and the increase in the uptake of non-oral, long-acting, reversible contraception (e.g., intrauterine devices, implants, injections) has corresponded to a decline in oral contraceptive pill use. Whether or not these other methods confer a protective effect against ovarian cancer in the general population is not clear. To our knowledge, there have been no such studies conducted among BRCA mutation carriers. Furthermore, the impact of these changes on the risk of developing ovarian cancer is not known. In this article, we will review the existing epidemiologic evidence regarding the role of contraceptives and the risk of ovarian cancer with a focus on women with a BRCA1 or BRCA2 mutation. We will discuss recent findings and gaps in the knowledge while extrapolating from studies conducted among women from the noncarrier population.https://doi.org/10.1186/s13053-022-00227-zBRCAOvarian cancerContraceptionIntrauterine deviceCase-control |
| spellingShingle | Yue Yin Xia Joanne Kotsopoulos Beyond the pill: contraception and the prevention of hereditary ovarian cancer Hereditary Cancer in Clinical Practice BRCA Ovarian cancer Contraception Intrauterine device Case-control |
| title | Beyond the pill: contraception and the prevention of hereditary ovarian cancer |
| title_full | Beyond the pill: contraception and the prevention of hereditary ovarian cancer |
| title_fullStr | Beyond the pill: contraception and the prevention of hereditary ovarian cancer |
| title_full_unstemmed | Beyond the pill: contraception and the prevention of hereditary ovarian cancer |
| title_short | Beyond the pill: contraception and the prevention of hereditary ovarian cancer |
| title_sort | beyond the pill contraception and the prevention of hereditary ovarian cancer |
| topic | BRCA Ovarian cancer Contraception Intrauterine device Case-control |
| url | https://doi.org/10.1186/s13053-022-00227-z |
| work_keys_str_mv | AT yueyinxia beyondthepillcontraceptionandthepreventionofhereditaryovariancancer AT joannekotsopoulos beyondthepillcontraceptionandthepreventionofhereditaryovariancancer |